BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, released an update from Chairman Richard Staelin, PhD, detailing sales growth, cost control, and strategic initiatives aimed at expanding its presence in the non-opioid pain management market.
The company reported a small profit for calendar year 2025 after relocating offices and reducing staff to align with operational needs. These cost control measures have allowed BioElectronics to focus on revenue-generating initiatives, including targeted advertising campaigns directed at medical professionals and healthcare providers. These campaigns aim to expand clinical awareness of RecoveryRx among surgeons, pain specialists, and other professionals seeking non-opioid pain management options.
Additionally, the company has expanded consumer-focused social media advertising targeting Generation X consumers to increase brand visibility for drug-free solutions for chronic musculoskeletal pain. As a result of these efforts, BioElectronics reported an increase in monthly sales in both the over-the-counter and professional markets.
Internationally, the company continues arbitration proceedings in Singapore against a former distributor for breach of contract, working with legal counsel and funders in China to protect its intellectual property and shareholder interests.
A significant development is the progress of the strategic distribution and licensing relationship with Electrome Corporation. Initial conditions of the supply agreement have been satisfied, with BioElectronics receiving Electrome's initial purchase order. Manufacturing is underway, and Electrome is planning a commercial launch of BioElectronics' pulsed shortwave therapy products through its platform. This milestone provides another pathway to increase consumer awareness and access to FDA-cleared, drug-free pain therapy products.
Staelin emphasized that this relationship is part of a broader strategy including clinical market development, direct professional outreach, consumer education, and international opportunities. The company is also working to identify a clinical trial partner for RecoveryRx to participate in a postoperative clinical study that could support future qualification for reimbursement under the federal NO PAIN Act initiative, representing a meaningful long-term opportunity.
Despite challenges faced by emerging medical technology companies, Staelin expressed optimism about growing interest in non-drug pain management solutions and the long-term potential of BioElectronics' technology platforms. The company remains focused on advancing initiatives that support sustainable growth and building long-term value for shareholders.
